ClinicalTrials.gg

Program

gemcitabine-oxaliplatin regimen

Also written as “TQB2825 injection + GemOx”, “GEMOX [gemcitabine+oxaliplatin]” and “Gemcitabine-Oxaliplatin”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung, led by 4 companies.

Furthest: phase 3, since May 25, 20204 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Antengene10 open or runningphase 2since May 25, 2020May 25, 2020none ahead
Jiangsu HengRui Medicine10 open or runningphase 2since Jun 28, 2021Jun 28, 2021none ahead
Sanofi10 open or runningphase 3since Jul 13, 2004Jul 13, 2004none ahead
Sino Biopharmaceutical11 open or runningphase 2since Feb 12, 2025Feb 12, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 13, 2004First study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to SanofiSanofi · NCT00087802 · 383 enrolled · United States
  2. May 25, 2020Antengene’s first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to AntengeneAntengene · NCT04425070 · 56 enrolled · China
  3. Jun 28, 2021Jiangsu HengRui Medicine’s first study: phase 2 study in RecurrenceNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04948788 · 102 enrolled · China
  4. Feb 12, 2025Sino Biopharmaceutical’s first study: phase 2 study in Lymphoma, Large B-Cell, DiffuseNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06829771 · 90 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06829771Lymphoma, Large B-Cell, Diffuse · China2RecruitingSino BiopharmaceuticalMay 202690
NCT04948788Recurrence · China2UNKNOWNJiangsu HengRui MedicineApr 2023102
NCT04425070Lymphoma, T-Cell, Peripheral · China2TerminatedAntengeneDec 30, 202556
NCT00087802Carcinoma, Non-Small-Cell Lung · United States3CompletedSanofiMay 2007383

How it is read

Names in the registry

  • “TQB2825 injection + GemOx”, 1 entry
  • “GEMOX [gemcitabine+oxaliplatin]”, 1 entry
  • “Gemcitabine-Oxaliplatin”, 1 entry
  • “gemcitabine/Eloxatin (GEMOX)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.